This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Clinical trial of anti-lymphocyte serum (ALS) as an immunosuppressive agent in patients with renal homografts has been reported by investigators at the University of Colorado Medical School.
Thomas E. Starzl, MD, and Thomas L. Marchioro, MD, told the annual Clinical Congress of the American College of Surgeons that serum derived from horses immunized against human lymphocytes has been used in 13 patients.
Preliminary results indicate that patients given ALS can be maintained on markedly reduced levels of steroids."The true effectiveness of antilymphocyte serum as an immunosuppressive agent in humans will not be known, however, until we can perform biopsies on patients receiving ALS," Dr. Starzl recently told JAMA Medical News.The report by the Denver group was one of several describing clinical experience with new immunosuppressive techniques.Others included a report by Nicholas L. Tilney, MD, and Joseph E. Murray, MD, on the use of thoracic duct
ALS Trials Prove Encouraging. JAMA. 1966;198(5):35-36. doi:10.1001/jama.1966.03110180015004